MiNK Therapeutics Files 2023 Annual Report on Form 10-K

TL;DR

<b>MiNK Therapeutics filed its 2023 10-K, detailing its operations and recent financing activities.</b>

AI Summary

MiNK Therapeutics, Inc. (INKT) filed a Annual Report (10-K) with the SEC on March 21, 2024. MiNK Therapeutics, Inc. filed its 2023 Form 10-K on March 21, 2024. The company was formerly known as AgenTus Therapeutics, Inc., with a name change on January 12, 2021. Key subsequent events include a Purchase Agreement for a Convertible Promissory Note with Agenus Inc. on February 12, 2024. The filing references research and development expenses and arrangements with entities like Agenus Inc. and Atlant Clinical Ltd. The company's business address is located at 149 Fifth Avenue, Suite 500, New York, NY 10010.

Why It Matters

For investors and stakeholders tracking MiNK Therapeutics, Inc., this filing contains several important signals. The 10-K filing provides a comprehensive overview of MiNK Therapeutics' financial health, operational status, and strategic direction for the fiscal year ending December 31, 2023. Recent financing events, such as the convertible promissory note agreement with Agenus Inc., are highlighted, indicating potential shifts in capital structure and future obligations.

Risk Assessment

Risk Level: medium — MiNK Therapeutics, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and significant R&D costs, as evidenced by the focus on research and development expenses and arrangements.

Analyst Insight

Monitor future filings for updates on the progress of clinical trials and the impact of the convertible promissory note financing on the company's cash position and debt.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period for the 10-K)
• 2024-03-21 — Filing Date (Date the 10-K was filed)
• 2021-01-12 — Name Change Date (Date AgenTus Therapeutics, Inc. became MiNK Therapeutics, Inc.)
• 2024-02-12 — Convertible Note Agreement Date (Date of Purchase Agreement for Convertible Promissory Note with Agenus Inc.)

Key Players & Entities

• MiNK Therapeutics, Inc. (company) — Filer name
• AgenTus Therapeutics, Inc. (company) — Former company name
• Agenus Inc. (company) — Party to a Purchase Agreement for Convertible Promissory Note
• 2024-03-21 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• 212-994-8250 (phone_number) — Business phone number
• 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010 (address) — Business address
• 2024-02-12 (date) — Date of Purchase Agreement for Convertible Promissory Note

FAQ

Risk Factors

• Risk Factors [high — financial]: The company faces risks related to its financial condition, including its ability to fund future operations and its reliance on external financing.
• Regulatory Approval Risk [high — regulatory]: Biotechnology companies are subject to extensive regulatory review and approval processes, which can be lengthy and uncertain.
• Research and Development Risk [high — operational]: The success of MiNK Therapeutics depends on the successful development and commercialization of its product candidates, which involves significant R&D risks.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT Nasdaq Capital Marke

Filing Documents

• inkt-20231231.htm (10-K) — 1830KB
• inkt-ex4_2.htm (EX-4.2) — 86KB
• inkt-ex10_18.htm (EX-10.18) — 97KB
• inkt-ex21_1.htm (EX-21.1) — 6KB
• inkt-ex23_1.htm (EX-23.1) — 3KB
• inkt-ex31_1.htm (EX-31.1) — 15KB
• inkt-ex31_2.htm (EX-31.2) — 15KB
• inkt-ex32_1.htm (EX-32.1) — 8KB
• inkt-ex32_2.htm (EX-32.2) — 8KB
• inkt-ex97_1.htm (EX-97.1) — 45KB
• img206969693_0.jpg (GRAPHIC) — 27KB
• img206969693_1.jpg (GRAPHIC) — 37KB
• img206969693_2.jpg (GRAPHIC) — 46KB
• img206969693_3.jpg (GRAPHIC) — 26KB
• 0000950170-24-034672.txt (&nbsp;) — 6871KB
• inkt-20231231.xsd (EX-101.SCH) — 1000KB
• inkt-20231231_htm.xml (XML) — 720KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 19 Item 1B. Unresolved Staff Comments 64 Item 1C. Cybersecurity 64 Item 2.

Properties

Properties 64 Item 3.

Legal Proceedings

Legal Proceedings 64 Item 4. Mine Safety Disclosures 64 PART II 65 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 65 Item 6. Reserved 65 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 66 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 70 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 71 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 87 Item 9A.

Controls and Procedures

Controls and Procedures 87 Item 9B. Other Information 87 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 87 PART III 88 Item 10. Directors, Executive Officers and Corporate Governance 88 Item 11.

Executive Compensation

Executive Compensation 88 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 88 Item 13. Certain Relationships and Related Transactions, and Director Independence 88 Item 14. Principal Accounting Fees and Services 88 PART IV 89 Item 15. Exhibits, Financial Statement Schedules 89 Item 16 Form 10-K Summary 90 i Note Regarding Forward Looking Statements This Annual Report on Form 10-K and other written and oral statements we make from time to time contain forward-looking statements. You can identify these forward-looking statements by the fact they use words such as "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will," "potential," "opportunity," "future" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Certain forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions. Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved, and rea

Bu siness

Item 1. Bu siness. MiNK Therapeutics, Inc. ("we," "us" and "our") is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T ("iNKT") cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer ("NK") cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease ("GvHD"). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with high unmet need. We are employing iNKT cells in their native form, through our lead program agenT-797, in diseases where iNKT cells have demonstrated activity and accelerated approval pathways exist. These indications include but are not limited to solid tumor cancers, acute respiratory distress ("ARDS") and other severe immune-related diseases, such as GvHD. Our discovery efforts are focused applying our proprietary technologies to build a broad pipeline of engineered iNKT cells, including TCRs, CAR-INKTS (such as, MiNK-215, FAP-CAR-iNKT and MiNK-413. BCMA-CAR-iNKT), and engager technology. 1 The following table summarizes our current product development pipeline: 1 Agenus Inc, therapeutic candidates botensilimab (BOT, Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). Our most advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNK

View Full Filing

View this 10-K filing on SEC EDGAR